Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–91.

Article  PubMed  Google Scholar 

EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85.

Butt SRR, Satnarine T, Ratna P, Sarker A, Ramesh AS, Munoz C, et al. A systematic review on current trends in the treatment of chronic hepatitis b to predict disease remission and relapse. Cureus. 2022;14: e32247.

PubMed  PubMed Central  Google Scholar 

Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8:2049936120985954.

CAS  PubMed  PubMed Central  Google Scholar 

Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs. 2003;12:683–8.

Article  CAS  PubMed  Google Scholar 

Cornberg M, Lok AS, Terrault NA, Zoulim F. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡). J Hepatol. 2020;72:539–57.

Article  CAS  PubMed  Google Scholar 

Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275–81.

Article  CAS  PubMed  Google Scholar 

Malcolm J, Falzone N, Lee BQ, Vallis KA. Targeted radionuclide therapy: New advances for improvement of patient management and response. Cancers (Basel). 2019;11(2):268.

Widel M. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy? Neoplasma. 2017;64:641–54.

Article  CAS  PubMed  Google Scholar 

Gannett PM, Sura TP. An improved synthesis of 8-bromo-2′-deoxyguanosine. Synth Commun. 1993;23:1611–5.

Article  CAS  Google Scholar 

Brancale A, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Bicyclic nucleoside inhibitors of varicella-zoster virus (VZV): the effect of a terminal halogen substitution in the side-chain. Bioorg Med Chem Lett. 2000;10:1215–7.

Article  CAS  PubMed  Google Scholar 

Cuzzupe AN, Hutton CA, Lilly MJ, Mann RK, McRae KJ, Zammit SC, et al. Total synthesis of the epidermal growth factor inhibitor (-)-reveromycin B. J Org Chem. 2001;66:2382–93.

Article  CAS  PubMed  Google Scholar 

McBride BJ, Baldwin RM, Kerr JM, Wu J-L. A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines. Int J Radiat Appl Instrum Part A Appl Radiat Isotopes. 1991;42:173–5.

Article  CAS  Google Scholar 

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.

Article  CAS  PubMed  Google Scholar 

Cai B, Chang S, Tian Y, Zhen S. CRISPR/Cas9 for hepatitis B virus infection treatment. Immun Inflamm Dis. 2023;11: e866.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang YC, Yang HC. Recent progress and future prospective in HBV cure by CRISPR/Cas. Viruses. 2021;14(1):4.

Gorsuch CL, Nemec P, Yu M, Xu S, Han D, Smith J, et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther. 2022;30:2909–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones DE, Vernon CA. Nucleophilic substitution in vinylic halides. Nature. 1955;176:791–2.

Article  ADS  CAS  Google Scholar 

Xie L. Inventor A novel iodine-containing antiviral agent. China patent ZL202011151673.9. 2020. https://www.qcc.com/zhuanliDetail/c0c32ae6ab39641ddca64010cb047cad.html.

Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41:1444–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019;4:27.

Article  PubMed  PubMed Central  Google Scholar 

Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75:706–17.

Article  CAS  PubMed  Google Scholar 

Panyutin IV, Sedelnikova OA, Bonner WM, Panyutin IG, Neumann RD. DNA damage produced by 125I-triplex-forming oligonucleotides as a measure of their successful delivery into cell nuclei. Ann N Y Acad Sci. 2005;1058:140–50.

Article  ADS  CAS  PubMed  Google Scholar 

Chen Q, Chen H, Wang W, Liu J, Liu W, Ni P, et al. Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition. Eur J Pharm Sci. 2017;106:313–27.

Article  CAS  PubMed  Google Scholar 

Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep. 2020;2: 100112.

Article  PubMed  PubMed Central  Google Scholar